Kurban S.Mehmeto?lu I.2020-03-262020-03-2620051300-0292https://hdl.handle.net/20.500.12395/19975Atherosclerosis is a multi-factorial disease. It has been demonstrated that low-density lipoproteins (LDL) are modified by free radicals and that this form of LDL is taken up by macrophages more easily. This modification of LDL has been assumed to be the most significant factor in the initiation and progression of atherogenesis. Oxidized low density lipoprotein (Ox-LDL) particles show chemotactic, cytotoxic and immunogenic properties. Ox-LDL expresses a large number of epitopes and cause production of polyclonal autoantibodies against these products. Especially, autoantibodies against apolipoprotein B100 (apoB100) modified by malondialdehyde (MDA) and 4-hydroxynonenal are produced. Ig-OxLDL may thus contribute to the formation of atherosclerosis. Antibodies against Ox-LDL have also been found in many diseases other than atherosclerosis, such as coronary artery disease (CAD), diabetes mellitus (DM), renovascular syndrome, uremia, acute infections, preeclampsia, antiphospholipid syndrome (APS), metabolic syndrome (MS), myocardial infarction (MI) and systemic lupus erythematosus (SLE). These antibodies might play an important role in the pathogenesis and diagnosis of a number of these diseases. However, these antibodies are highly heterogeneous and present information concerning them is quite limited. In this review, we have aimed to evaluate current research regardinging Ox-LDL and its antibodies. Copyright © 2005 by Türkiye Klinikleri.trinfo:eu-repo/semantics/openAccessArteriosclerosisCoronary arteriosclerosisOxidized low density lipoproteinReview2517384Q4